Anida Pharma is utilizing the potential of resolution biology to develop novel treatment paradigms to prevent and restore
sensory organ dysfunction.
WHO WE ARE
Anida is a preclinical-stage biopharmaceutical company leveraging the knowledge around the body’s own homeostatic and protective mechanisms to develop targeted therapeutics in the fields of vision and hearing. The combination of the unique discoveries in Dr. Charles Serhan’s Laboratory at Harvard Medical School with our team’s extensive drug development experience has enabled us to develop a pipeline of treatments that targets sensory organ dysfunction and with an initial focus on high unmet medical needs in pediatric and adult patients:
Retinopathy of prematurity;
Drug-induced hearing loss caused by cancer chemotherapy – pediatric and adult;
The immune system is critical for an organism’s integrity and survival. However, an excessive immune response is associated with tissue death and dysfunctional repair, and may lead to chronic organ failure or even become deleterious. To prevent permanent loss of function the body has adopted highly specific counter-mechanisms, which if activated may offer unique therapeutic advantages. Anida’s drug in development, AP-001, is an endogenous lipid-derived agonistic small molecule from the DHA metabolome. AP-001 acts on several pathways to ensure system integrity (see figure). By independently regulating inflammation, cell death and tissue repair, both epithelial and nerve regrowth, AP-001 addresses the need to control for the redundancy of pathological mechanisms associated with acute events and chronic conditions. These may be caused by an infection, trauma, or aberrant tissue response due to changed physiological conditions, and are further exemplified by Anida’s targeted treatment indications. AP-001 is in the scientific literature referred to as neuroprotectin D1 (NPD1) or protectin D1 (PD1).
Sensory Organ Research Extensions
Using our platform and knowledge base Anida is at research stage exploring novel treatment options for a broader range of corneal and retinal disorders which are currently underserved. Anida is also working at identifying treatments to restore the hearing in individuals suffering age- and noise-related hearing loss.
Our first-in-class drug programs address the imminent risk of vision loss in very early born infants, permanent hearing loss caused by cancer chemotherapy, and chronic later-in-life vision and hearing conditions. Our unique drug development approach will ensure the rapid access of our treatments for use in both pediatric orphan and adult indications.
SCIENTIFIC AND CLINICAL ADVISOR AND COLLABORATORS
Charles N. Serhan, PhD, DSc
Chair Anida Scientific Advisory Board
Director, Center for Experimental Therapeutics and Reperfusion Injury
Brigham and Women’s Hospital
The Simon Gelman Professor of Anaesthesia, Harvard Medical School
Anida Pharma Inc.
155 Brookline Street, Suite 005
Cambridge, MA 02139
Tel: 617 331 5033